First Manhattan
SABS icon

First Manhattan’s SAB Biotherapeutics SABS Stock Holding History

First Manhattan’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-24,577
Closed -$66.4K – 704
2024
Q3 		$66.4K Hold
24,577
– – ﹤0.01% 672
2024
Q2 		$76.2K Hold
24,577
– – ﹤0.01% 654
2024
Q1 		$112K Sell
24,577
-3,201
-12% -$17.6K ﹤0.01% 752
2023
Q4 		$191K Hold
27,778
– – ﹤0.01% 649
2023
Q3 		$175K Hold
27,778
– – ﹤0.01% 674
2023
Q2 		$231K Hold
27,778
– – ﹤0.01% 634
2023
Q1 		$122K Buy
+27,778
New +$176K ﹤0.01% 769

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Manhattan's SABS Position: Q4 2024 in Review

First Manhattan sold out of SAB Biotherapeutics (SABS) in Q4 2024, closing a stake of 24,577 shares — an estimated $66.4K sold.

First Manhattan first reported a position in SABS in Q1 2023 and held it in 7 quarters. The position peaked at $231K in Q2 2023. 25 funds tracked by Wall St. Rank hold SABS as of Q4 2024.

  • First Manhattan reported no remaining SAB Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • First Manhattan sold 24,577 SAB Biotherapeutics shares in Q4 2024, an estimated $66.4K.
  • First Manhattan first reported a position in SAB Biotherapeutics in Q1 2023 and held it in 7 quarters.
  • First Manhattan's SAB Biotherapeutics position peaked at $231K in Q2 2023.
  • 25 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2024.

Based on First Manhattan's 13F filing for Q4 2024, filed 14 Feb 2025.